EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cancer-derived inflammation is associated with bevacizumab resistance and inferior clinical outcomes in patients with metastatic colorectal cancer

Ya-Nan Li iD, Yang Wu iD, Feng-Wen Deng iD, Ying Lu iD, Guo-Bin Song iD, Lin Xiang iD, Tian Peng iD, Xue-Xin Cheng iD, Hou-Qun Ying iD

Therapeutic Advances in Medical Oncology · 2026-01 · 18

DOI: 10.1177/17588359251411086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 07.01.2026. Verfasst von Ya-Nan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Cl…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Second Affiliated Hospital of Nanchang University Funding Program, The Jiangxi Provincial Postgraduate Innovation Special Fund Project, The National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer-derived inflammation has been shown to attenuate the efficacy of chemotherapy (CT) in colorectal cancer. However, its role in clinical response to bevacizumab (Bev) remains unclear in patients with metastatic colorectal cancer (mCRC).

Objectives

To investigate the clinical significance of the fibrinogen-to-prealbumin ratio (FPR) as a biomarker in mCRC patients receiving first-line Bev plus CT (Bev/CT).

Design

A retrospective, single-center, observational study.

Methods

Patients treated with first-line Bev/CT were enrolled across discovery ( n = 249), internal validation ( n = 115), and external validation ( n = 109) cohorts, along with a patient group receiving CT alone ( n = 175). Propensity score matching was performed to balance baseline characteristics between the Bev/CT- and CT-treated groups. The primary endpoints were disease control rate (DCR) and progression-free survival (PFS), and 1-year overall survival (OS) was designated as a secondary endpoint.

Results

Elevated pretreatment FPR was significantly associated with increased tumor burden. FPR-H patients exhibited an unfavorable DCR compared to the FPR-L patients in the overall Bev/CT-treated population (adjusted odds ratio (OR) = 2.18, 95% confidence interval (CI) = 1.32–3.61, p < 0.01). FPR-H was also independently associated with shorter PFS in the discovery ( p log-rank < 0.01, adjusted hazard ratio (HR) = 1.51, 95% CI = 1.11–2.05), internal validation ( p log-rank < 0.01, adjusted HR = 2.47, 95% CI = 1.43–4.27), and external validation cohorts ( p log-rank < 0.001, adjusted HR = 2.28, 95% CI = 1.43–3.64), regardless of KRAS status, particularly in the microsatellite stable subgroup. Furthermore, FPR-H patients had significantly worse 1-year OS than the FPR-L subgroup in the overall population ( p log-rank < 0.001; adjusted HR = 2.86, 95% CI = 1.78–4.61). Dynamic monitoring of FPR demonstrated utility in tracking disease progression during Bev/CT treatment, with earlier detection capability compared to imaging-based assessment. In propensity score-matched analysis, patients receiving Bev/CT showed superior outcomes relative to those receiving CT alone ( p log-rank < 0.001), especially among the FPR-L subgroup ( p log-rank < 0.01). In addition, Bev/oxaliplatin-treated FPR-L cases achieved better outcomes than those receiving the Bev/irinotecan regimen, particularly in the subgroup undergoing palliative resection.

Conclusion

Cancer-derived inflammation appears to play a crucial role in mediating both intrinsic and acquired resistance to Bev. The FPR emerges as a robust, independent biomarker for predicting response to Bev, monitoring disease progression, and informing personalized therapeutic decision-making in patients with mCRC.

Schlagwörter

Stichwörter der Autor:innen

bevacizumabcolorectal cancerfibrinogen-to-prealbumin ratioinflammationtherapeutic resistance

Autor:innen und Institutionen

  • Jiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical Col…
  • Daye People's Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei, China.
  • Department of Clinical Laboratory, Immunity and Inflammation Key Laboratory of Jiangxi Province, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang, Jiangxi 330006, China.
  • Department of Laboratory Medicine, Central Hospital of Shangrao City, Shangrao, Jiangxi, China.
  • Shangrao Medical Center of The Second Affiliated Hospital of Nanchang University, Shangrao, Jiangxi, China.

ORCID-Profile: Ya-Nan Li, Yang Wu, Feng-Wen Deng, Ying Lu, Guo-Bin Song, Lin Xiang, Tian Peng, Xue-Xin Cheng, Hou-Qun Ying

Förderung

  • The Second Affiliated Hospital of Nanchang University Funding Program
  • The Jiangxi Provincial Postgraduate Innovation Special Fund Project
  • The National Natural Science Foundation of China

Zitieren

APA

Li, Y. N., Wu, Y., Deng, F. W., Lu, Y., Song, G. B., Xiang, L., Peng, T., Cheng, X. X., & Ying, H. Q. (2026). Cancer-derived inflammation is associated with bevacizumab resistance and inferior clinical outcomes in patients with metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359251411086

Vancouver

Li YN, Wu Y, Deng FW, Lu Y, Song GB, Xiang L, et al. Cancer-derived inflammation is associated with bevacizumab resistance and inferior clinical outcomes in patients with metastatic colorectal cancer. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359251411086

BibTeX
@article{Li2026,
  author = {Li, Ya-Nan and Wu, Yang and Deng, Feng-Wen and Lu, Ying and Song, Guo-Bin and Xiang, Lin and Peng, Tian and Cheng, Xue-Xin and Ying, Hou-Qun},
  title = {Cancer-derived inflammation is associated with bevacizumab resistance and inferior clinical outcomes in patients with metastatic colorectal cancer},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359251411086}
}
Kostenlos starten →